Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Single Arm, Open-label, Early Feasibility Study to Evaluate Initial Safety and Device Design Concept of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension on Three(3) or More Antihypertensive Medications
Conditions
Interventions
HyperQureTM Renal Denervation (RDN) System:
Locations
5
United States
University of California Irvine
Orange, California, United States
Stanford Health Care
Stanford, California, United States
University of Florida College of Medicine
Gainesville, Florida, United States
Henry Forth Health
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
November 21, 2024
Primary Completion Date
June 18, 2026
Completion Date
March 20, 2029
Last Updated
December 4, 2025
NCT04388124
NCT07081243
NCT06940011
NCT06515795
NCT06228677
NCT06829537
Lead Sponsor
DeepQure Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions